#United States #Chicago #Lung Cancer #Biomarker Testing #American Lung Association

Each Lung Cancer Journey is Unique

Lung cancer poses significant health challenges, as it ranks as the second most commonly diagnosed cancer in the United States, along with being the leading cause of cancer-related deaths. The statistical forecast indicates that over 229,000 individuals will receive a lung cancer diagnosis in 2026, highlighting a daily influx of over 600 new cases. Among these, non-small cell lung cancer (NSCLC) accounts for about 80% of all diagnoses. In light of these statistics, the American Lung Association (ALA) is taking crucial steps to amend this grim narrative through the launch of its BEAT Lung Cancer initiative.

The BEAT Lung Cancer Initiative

This innovative initiative is designed to provide comprehensive support and resources to those affected by lung cancer. It focuses on the importance of biomarker testing, which is essential for determining the most effective treatment options for patients. As emphasized by Harold Wimmer, President and CEO of ALA, significant advancements in medical research and treatment have dramatically improved survival rates, climbing to nearly 30% in the past five years. These enhancements hinge on optimal access to healthcare services and informed decisions facilitated by proper resources.

New Educational Resources

The campaign aims to guide newly diagnosed patients towards understanding the importance of biomarker testing and the benefits of targeted treatments. Among the key elements of the initiative are:

• - Biomarker FAQs: A resource designed to assist individuals with common inquiries regarding biomarker testing, discussing its significance and facilitating conversations with healthcare providers.
• - Detailed Breakdown of Biomarkers: A dedicated website section featuring 12 actionable biomarkers associated with lung cancer, alongside resources on testing protocols, interpreting results, and next steps. Video content is available for an accessible understanding of complex information.
• - Find Your Path Tool: This user-friendly web tool connects individuals at various stages of their lung cancer journey with personalized resources. The tool ensures quick access to tailored information based on their specific situation, whether they are considering screenings or seeking treatment options.

The Role of Biomarker Testing

Biomarker testing, also known as molecular or genomic testing, is pivotal as it evaluates DNA and specific protein levels within a patient's tumor. This vital diagnostic approach allows healthcare providers to pinpoint what drives tumor growth, assisting patients in accessing targeted therapies that may slow tumor progression or reduce tumor size. Moreover, it evaluates the levels of the PD-L1 protein, which offers insights into potential immunotherapy benefits.

Despite its importance, biomarker testing is underutilized. A concerning study revealed that 23% of lung cancer patients underwent chemotherapy and radiation therapy before undergoing full biomarker testing, which can lead to unnecessary treatment and wasted time. Barriers such as lack of awareness and gaps in insurance coverage often hinder patients from obtaining this crucial testing.

The BEAT Lung Cancer initiative, supported by key pharmaceutical partners including Eli Lilly, Merck, and AstraZeneca, strives to surmount these barriers by:

• - Raising awareness about the significance of lung cancer screening and biomarker testing among patients and their communities.
• - Offering free support through Lung Health Navigators, who assist patients throughout their lung cancer journey.
• - Educating newly diagnosed individuals on how to effectively communicate with their healthcare providers about biomarker testing.

Conclusion

The American Lung Association continues to pave the way in lung cancer advocacy and education. By amplifying the conversation surrounding lung cancer, the BEAT Lung Cancer initiative seeks to empower individuals with the knowledge and resources necessary for confronting their unique challenges. To explore further information and resources, visit Lung.org/beat-lung-cancer and join the fight against lung cancer.

For more information about the American Lung Association and its initiatives, contact:
Jill Dale | American Lung Association
Phone: 312-940-7001
Email: [email protected]